METHOD OF DIAGNOSING EARLY STAGE NON-SMALL CELL LUNG CANCER

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20130252831A1
SERIAL NO

13891433

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A “malignancy-risk” (MR) gene signature score was developed with abundant proliferative genes using principal component analysis. This MR gene signature was shown to be a predictive and prognostic factor of overall survival in early-stage NSCLC. The malignancy-risk signature showed a significant association with OS, with poor survival seen in patients having a higher MR score and better survival seen in patients having a low MR score. As a prognostic factor, the MR gene signature showed a positive correlation with TNM stage, histologic grade, and smoking status. Combination of the MR signature with each clinical parameter often showed the best survival in the low MR group with good clinical outcome. The MR gene profile, tested with a PCA scoring method, discriminated overall survival in lung cancer patients was a predictor independent of pathological staging and other clinical parameters.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE INC12902 MAGNOLIA DRIVE TAMPA FL 33612-9497

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Dung-Tsa Tampa, US 14 44

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation